Physician

Martha Motuz Leen, MD

According to 2025 Medicare claims, Martha Leen, MD (NPI: 1093716458) practices ophthalmology in the Bremerton-Silverdale-Port Orchard, WA market, with the plurality of this provider's patient population coming from Kitsap, WA. This provider's primary affiliated billing organization is EYE CLINIC OF BREMERTON, INC. P.S. (NPI: 1831228311; TIN: 911013662) and primary practice location at 98383-6000. Leen is affiliated with the Jefferson Accountable Care, LLC (ACO ID: A5275), participating under the MSSP model.

Leen's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 833 traditional Medicare patients, billed 4,550 HCPCS/CPT codes, and received $338,878 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 2,677 prescription claims across 631 beneficiaries totaling $270,303 in drug costs, led by Rhopressa (Netarsudil Mesylate). 2019 DME data shows 38 claims. Open Payments data shows 14 records totaling $507. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs did not follow a clear longitudinal pattern. In contrast, DME billing represents a smaller volume and changed little.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	832	4,141	$405,619
2016	911	4,676	$458,777
2017	925	4,815	$462,424
2018	934	4,697	$452,958
2019	965	4,923	$476,303
2020	886	4,043	$354,108
2021	990	4,646	$407,703
2022	890	4,137	$370,363
2023	894	4,229	$386,073
2024	833	4,550	$338,878

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	335	2,159	$214,892
2016	360	2,234	$226,962
2017	372	2,358	$247,540
2018	394	2,308	$273,400
2019	361	1,556	$201,077
2020	359	1,364	$179,809
2021	392	1,339	$174,064
2022	398	1,327	$159,097
2023	488	2,018	$253,437
2024	631	2,677	$270,303

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	12	12	$575
2016	44	45	$3,211
2017	13	13	$671
2018	17	17	$794
2019	38	38	$2,639
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	491	1,040	$85
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	525	878	$64
92083	Exam of visual field with extended testing	508	555	$44
92133	Imaging of optic nerve	527	542	$26
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	343	797	$13

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Rhopressa	Netarsudil Mesylate	80	3,298	$38,446
Restasis	Cyclosporine	25	1,800	$35,335
Lumigan	Bimatoprost	36	2,447	$22,619
Vyzulta	Latanoprostene Bunod	24	1,632	$15,742
Rocklatan	Netarsudil Mesylat/Latanoprost	22	1,096	$13,136

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	14	$507	Alcon Vision LLC
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Martha Motuz Leen, MD?

Tedicare shows public-source Medicare data for Martha Motuz Leen, MD (NPI 1093716458), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Martha Motuz Leen, MD have ACO affiliation data?

Martha Motuz Leen, MD is shown with ACO affiliation data for Jefferson Accountable Care, LLC (MSSP, ACO ID A5275).

What billing organization is linked to Martha Motuz Leen, MD?

Martha Motuz Leen, MD is linked to EYE CLINIC OF BREMERTON, INC. P.S. (billing NPI 1831228311) in the available physician profile data.

Does Martha Motuz Leen, MD have Open Payments data?

Martha Motuz Leen, MD has 14 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.